The�Berkshire Hathaway� (NYSE: BRK-A ) (NYSE: BRK-B ) annual meeting is in full gear and Warren Buffett and Charlie Munger are on the hot seat in front of tens of thousands of shareholders. Here are a few great investing quotes that Buffett has delivered during the meeting.
1.�"Capital ratios for larger banks are being set higher than smaller banks and that obviously impacts return on equity."
Does that sound like a pessimistic take on the banking industry? It's certainly not the most optimistic take. However, Buffett followed that line up by saying:
I feel very good about our investment in Wells Fargo� (NYSE: WFC ) , I feel very good about our investment in US Bancorp� (NYSE: USB ) , I feel very good about our investment in M&T Bank� (NYSE: MTB ) .
Are these contradictory sentiments? Hardly. This is Buffett owning up to the fact that it's going to be tougher on banks in the years to come because of higher capital requirements, but that investors can still do well investing in banks provided they focus on finding the best banks with high-quality management.
Top 10 Cheapest Stocks To Invest In Right Now: Tetraphase Pharmaceuticals Inc (TTPH)
Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company�� product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company are developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. The Company�� frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. In 2012, in vitro experiments, eravacycline has demonstrated the ability to cover a variety of multi-drug resistant Gram-negative, Gram-positive, anaerobic and atypical bacteria, including multi-drug resistant Klebsiella pneumoniae, the species of Gram-negative bacteria that killed seven patients at the Clinical Center of the National Institutes of Health.
Gram-positive bacteria that have developed resistance to existing drugs include: Streptococcus pneumoniae that cause pneumonia, ear infections, bloodstream infections and meningitis; Staphylococcus aureus that cause skin, bone, lung and bloodstream infections, and Enterococci that are responsible for infections transmitted in healthcare settings. Gram-negative bacteria that have developed resistance to existing drugs include: Escherichia coli that cause urinary tract, skin and bloodstream infections; Salmonella and Escherichia coli that cause foodborne infections, and Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp.
In addition, other antibiotics that have been used as first-line empiric monothe! rapies, such as Levaquin, piperacillin/tazobactam, which is marketed by Pfizer as Zosyn, carbapenems, such as Merrem, and imipenem/cilastatin, which is marketed by Merck as Primaxin, have seen their utility as first-line empiric monotherapies diminished as the number of bacterial strains resistant to these therapies has increased. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. A number of previous tetracyclines have been available in both intravenous and oral dosage forms. Infections that are resistant to existing oral drugs are increasingly common, and the Company believe that an intravenous-to-oral step-down therapy in which patients are started on the intravenous formulation of eravacycline and then stepped down to an oral formulation of eravacycline could reduce the length of a patient�� hospital stay or help avoid hospital admission altogether, lowering the overall cost of care for these patients.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Tetraphase Pharmaceuticals (TTPH), which using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. This stock is off to a strong start in 2013, with shares up 19.4%.
If you take a look at the chart for Tetraphase Pharmaceuticals, you'll notice that this stock has just started to trend back above its 50-day moving average of $7.76 a share with decent upside volume flows. That move is quickly pushing shares of TTPH within range of breaking out above some key near-term overhead resistance levels that have acted as a ceiling for the stock for the last three months.
Market players should now look for long-biased trades in TTPH if it manages to break out above some near-term overhead resistance levels at $8.30 to $8.40 a share and then once it takes out more resistance at $8.50 to $9 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 62,234 shares. If that breakout triggers soon, then TTPH will set up to re-test or possibly take out its all-time high at $9.66 a share. Any high-volume move above that level will then push TTPH into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $12 to $13 a share.
Traders can look to buy TTPH off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $7.76 a share, or below more key near-term support levels at $7.37 to $7.02 a share. One can also buy TTPH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 Warren Buffett Companies For 2014: Stemline Therapeutics Inc (STML)
Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.
SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.
SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk
SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.
SL-701
SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.
StemScreen-1
StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.
StemScreen-2
StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.
The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.
Advisors' Opinion:- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
- [By Keith Speights]
Best-performing biotech IPO
Stemline Therapeutics� (NASDAQ: STML ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%. - [By David Zeiler]
3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.
Top 10 Warren Buffett Companies For 2014: Markel Corp (MKL)
Markel Corporation is a financial holding company serving a range of markets. The Company markets and underwrites specialty insurance products. The Company operates in three segments: the Excess and Surplus Lines, the Specialty Admitted, and the London markets. It also owns interests in industrial and service businesses, which operate outside of the specialty insurance marketplace. On January 1, 2012, the Company acquired Thompson Insurance Enterprises, LLC (THOMCO). On July 13, 2011, the Company acquired PartnerMD, LLC. On October 19, 2011, the Company acquired an 83% interest in WI Holdings Inc. (Weldship). In April 2012, its subsidiary, Markel Ventures, acquired a majority interest in Havco WP LLC. In July 2012, Markel Corporation announced that Ellicott Dredge Enterprises, LLC, through its subsidiary Rohr International Dredge Holdings, Inc., acquired IDRECO GmbH. In January 2013, OneBeacon Insurance Group Ltd sold Essentia Insurance Company to the Company. In May 2013, it announced that it has completed its acquisition of Alterra Capital Holdings Ltd.
Excess and Surplus Lines Segment
Business in the Excess and Surplus Lines segment is written through two distribution channels, professional surplus lines general agents who have limited quoting and binding authority and wholesale brokers. The business produced by this segment is written on a surplus lines basis through either Essex Insurance Company or Evanston Insurance Company. During the year ended December 31, 2011, in the Excess and Surplus Lines segment, it wrote business through regional underwriting offices, which include Markel Northeast (Red Bank, NJ), Markel Southeast (Glen Allen, VA), Markel Midwest (Deerfield, IL), Markel Mid South (Plano, TX) and Markel West (Woodland Hills, CA and Scottsdale, AZ). Product offerings within the Excess and Surplus Lines segment fall within the product groupings, which include Property and Casualty, Professional Liability, and Other Product Lines. Property coverages consist of f! ire, allied lines (including windstorm, hail and water damage) and other specialized property coverages, including catastrophe-exposed property risks, such as earthquake and wind on both a primary and excess basis. Its property risks range from small, single-location accounts to multi-state, multi-location accounts. Casualty product offerings include a range of liability coverages targeting apartments and office buildings, retail stores, contractors and recreational and hospitality businesses. It also offers products liability coverages on either an occurrence or claims-made basis to manufacturers, distributors, importers and re-packagers of manufactured products.
Professional liability coverages include solutions for specialized professions, including architects and engineers, lawyers, agents and brokers, service technicians and computer consultants. It offers claims-made medical malpractice coverage for doctors, dentists and podiatrists; claims-made professional liability coverage to individual healthcare providers, such as therapists, pharmacists, physician assistants and nurse anesthetists, and coverages for medical facilities and other allied healthcare risks, such as clinics, laboratories, medical spas, home health agencies, small hospitals, pharmacies and nursing homes. This product line also includes for-profit and not-for profit management liability coverage, which can be bundled or written mono-line and include employment practices liability, directors��and officers��liability and fiduciary liability coverages. In addition, it offers a data privacy and security product, which provides coverage for data breach and privacy liability, data breach loss to insureds and electronic media coverage.
Other product lines within the Excess and Surplus Lines segment include excess and umbrella products, which provide coverage over approved underlying insurance carriers on either an occurrence or claims-made basis; environmental products, which include environmental consultants! ��profe! ssional liability, contractors��pollution liability and site-specific environmental impairment liability coverages; transportation-related products, which provide auto physical damage coverage for automobiles, as well as all types of specialty commercial vehicles, dealers��open lot and garagekeeper legal liability coverages, vehicular liability and physical damage coverages for local and intermediate haul commercial trucks and liability coverage to operators of small to medium-sized owned and operated taxicab fleets, non-emergency ambulances and multi-line specialty products designed for the characteristics of the garage industry; inland marine products, which provide a range of specialty coverages for risks, such as motor truck cargo coverage for damage to third party cargo while in transit, warehouseman�� legal liability coverage for damage to third party goods in storage, contractors��equipment coverage for first party property damage and builder�� risk coverage; ocean marine products, which provide general liability, professional liability, property and cargo coverages for marine artisan contractors, boat dealers and marina owners, including hull physical damage, protection and indemnity and third party property coverages for ocean cargo; casualty facultative reinsurance written for individual casualty risks focusing on general liability, products liability, automobile liability and certain classes of professional liability and targeting classes, which include general liability risks; railroad-related products, which provide first and third party coverages for short-line and regional railroads, scenic and tourist railroads, commuter and light rail trains and railroad equipment, and public entity insurance and reinsurance programs, which provide coverage for government entities including counties, municipalities, schools and community colleges.
Specialty Admitted Segment
The business in the Specialty Admitted segment is written by retail insurance agents who have v! ery limit! ed underwriting authority. Products and programs are marketed directly to consumers or distributed through wholesale producers. Personal lines coverages included in this segment are marketed directly to the consumer using direct mail, Internet and telephone promotions, as well as relationships with various motorcycle and boat manufacturers, dealers and associations. The business produced by this segment is written on an admitted basis either through Markel Insurance Company (MIC), Markel American Insurance Company (MAIC) and FirstComp Insurance Company (FCIC).
The Markel Specialty unit focuses on providing total insurance programs for businesses engaged in specialized activities. The Markel Specialty unit is organized into product areas, which concentrate on particular markets and customer groups, including youth and recreation oriented organizations, social service organizations, amateur sports organizations and horse and farm operations. The Markel American Specialty Personal and Commercial Lines unit offers its insurance products focuses its underwriting on marine, recreational vehicle, property and other personal and commercial line coverages. The FirstComp unit provides workers��compensation insurance and related services, to small businesses. The FirstComp unit distributes its products through independent insurance agencies.
Product offerings within the Specialty Admitted segment fall within product groupings, which include Workers��Compensation, Property and Casualty, Personal Lines, Accident and Health, and Other Product Lines. Workers��compensation products provide wage replacement and medical benefits to employees injured in the course of employment and target main-street, service and artisan contractor businesses, retail stores and restaurants. Property and casualty products included in this segment are offered on a monoline or package basis and target commercial markets and customer groups. Targeted groups include youth and recreation oriented organizations,! social s! ervice organizations, museums and historic homes, performing arts organizations, bed and breakfast inns, outfitters and guides, hunting and fishing lodges, dude ranches and rod and gun clubs. Personal lines products provide first and third party coverages for a range of personal watercrafts, including older boats, boats and yachts, as well as for recreational vehicles, including motorcycles, snowmobiles and all terrain vehicles (ATVs). In addition, property coverages are offered for mobile homes, dwellings and homeowners that do not qualify for standard homeowner�� coverage. Other products offered include special event protection, supplemental natural disaster coverage, renters��protection coverage, excess flood coverage and collector vehicle coverage. Accident and health products offer liability and accident insurance for amateur sports organizations, accident and medical insurance for academic institutions, monoline accident and medical coverage for various markets, short-term medical insurance, pet health insurance, stop-loss insurance for self-insured medical plans and medical excess reinsurance coverage.
Other product lines within the Specialty Admitted segment include coverages for equine-related risks, such as horse mortality, theft, infertility, transit and specified perils, as well as property and liability coverages for farms and boarding, breeding and training facilities; first and third party coverages for auto repair garages, gas stations and convenience stores and used car dealers; general agent programs, which use managing general agents to offer single source admitted and non-admitted programs for a specific class or line of business; first and third party coverages for small fishing ventures, charters, utility boats and boat rentals, and professional liability coverages, which it designs and administers on behalf of other insurance carriers and ultimately assume on a reinsurance basis.
London Insurance Market Segment
This segment is consisted o! f Markel ! International. Markel International writes specialty property, casualty, professional liability, equine, marine, energy and trade credit insurance on a direct and reinsurance basis. Business is written worldwide through either Markel International Insurance Company Limited (MIICL) or Markel Syndicate 3000 with approximately 15% of writings coming from the United States. Product offerings within the London Insurance Market segment fall within the product groupings, which include Marine and Energy, Professional and General Liability, Reinsurance, Property, and Other Product Lines.
Marine and energy products include a portfolio of coverages for cargo, energy, hull, liability, war, terrorism and specie risks. The cargo account is an international transit-based book covering a range of cargo. Energy coverage includes all aspects of oil and gas activities. The hull account covers physical damage to ocean-going tonnage, yachts and mortgagee�� interest. Liability coverage provides for a range of energy liabilities, as well as marine exposures, including charterers, terminal operators and ship repairers. The war account covers the hulls of ships and aircraft, and other related interests, against war and associated perils. Terrorism coverage provides for property damage and business interruption related to political violence, including war and civil war. The specie account includes coverage for fine art on exhibition and in private collections, securities, bullion, precious metals, cash in transit and jewelry.
Professional and general liability products include professional indemnity, directors��and officers��liability, intellectual property, some defense costs, incidental commercial crime, general and products liability coverages targeting consultants, construction professionals, financial service professionals, professional practices, social welfare organizations and medical products. Professional and general liability products are written on a global basis. Reinsurance products ! include p! roperty and casualty treaty reinsurance. Property treaty products are offered on an excess of loss and proportional basis for per risk and catastrophe exposures. A portion of the excess of loss catastrophe and per risk property treaty business comes from the United States with the remainder coming from international property treaties. Casualty treaty reinsurance is offered on an excess of loss basis and targets specialist writers of motor products in the United Kingdom and Europe. Excess of loss casualty treaty reinsurance also is offered for select writers of employers��and products liability coverages.
Property products target a range of insureds, providing coverage ranging from fire to catastrophe perils, such as earthquake and windstorm. Business is written either in the open market or on a delegated authority basis for direct and facultative risks. Open market business is written mainly on a global basis by its underwriters to London brokers, with each risk being considered on its own merits. The Company provides property coverage for small to medium-sized commercial risks on both a stand-alone and package basis through its branch offices. Other product lines within the London Insurance Market segment include crime coverage targeting financial institutions and providing protection for bankers��blanket bond, computer crime and commercial fidelity; contingency coverage, including event cancellation, non-appearance and prize indemnity; accident and health coverage for affinity groups and schemes, risks accounts and sports groups; coverage for equine-related risks, such as horse mortality, theft, infertility, transit and specified perils; specialty coverages include mortality risks for farms, zoos, animal theme parks and safari parks; short-term trade credit coverage for commercial risks, including insolvency and protracted default, as well as political risks coverage in conjunction with commercial risks for currency inconvertibility, government action, import/export license cancellati! on, publi! c buyer default and war, and products liability, excess and umbrella and environmental liability coverages.
The Company purchases reinsurance. It purchases catastrophe reinsurance coverage for its catastrophe-exposed policies. In addition, certain foreign reinsurers for its United States insurance operations must provide collateral equal to 100% of recoverable, with the exception of reinsurers who have been granted authorized status by an insurance company�� state of domicile. When appropriate, it pursues reinsurance commutations, which involve the termination of ceded reinsurance contracts. Reinsurance treaties are purchased on an annual basis.
Advisors' Opinion:- [By Dan Caplinger]
That business model has been so successful that other, smaller insurance companies have emulated it. For instance, Fairfax Financial (NASDAQOTH: FRFHF ) and Markel (NYSE: MKL ) have used the same investing model to take advantage of their respective core insurance businesses. Both Fairfax and Markel have had substantial success, showing the power of using temporarily available premium reserves to make higher-return investments.
Top 10 Warren Buffett Companies For 2014: Atrion Corp (ATRI)
Atrion Corporation (Atrion), and its subsidiaries, develop and manufacture products, primarily for medical applications. The Company�� medical products range from fluid delivery devices to ophthalmic and cardiovascular products. During the year ended December 31, 2011, the Company�� fluid delivery products accounted for 38% of the Company�� revenues. These products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes, and produce specialized intravenous sets for use in numerous applications, including anesthesia and oncology.
The Company�� cardiovascular products accounted for 29% of its revenues during 2011. The Company's principal cardiovascular product is the Myocardial Protection System (MPS2), a technology that delivers essential fluids and medications to the heart during open-heart surgery. The MPS2 integrates key functions relating to the delivery of solutions to the heart, such as varying the rate and ratio of oxygenated blood, crystalloid, potassium and other additives, and controlling temperature, pressure and other variables to allow simpler, more flexible management of this process, indicating improved patient outcomes. The MPS2 is the device used in open-heart surgery that allows for the mixing of drugs into the bloodstream without diluting the blood. The MPS2 employs advanced pump, temperature control and microprocessor technologies and includes a line of disposable products. It also develops and manufactures other cardiovascular products that include cardiac surgery vacuum relief valves; Retract-O-Tape silicone vessel loops for retracting and occluding vessels in minimally inva! sive surgical procedures; inflation devices for balloon catheter dilation, stent deployment and fluid dispensing, and Clean-Cut rotating aortic punch and PerfectCut Aortotomy System, both of which are used in heart bypass surgery to make a precision opening in the heart for attachment of the bypass vessels.
The Company�� ophthalmic products accounted for 17% of its revenues during 2011. The Company is a manufacturer of contact lens disinfection cases. It also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. The Company�� other medical and non-medical products accounted for 16% of its revenues during 2011. These product lines consist of instrumentation and associated disposables used to measure the activated clotting time of blood. In addition, it manufactures and sells a line of products designed for safe needle and scalpel blade containment. It is also the manufacturer of inflation systems and valves used in marine and aviation safety products. The Company manufactures inflation systems and valves for products, such as life vests, life rafts, inflatable boats, survival equipment and other inflatable structures. The Company also produces one-way and two-way pressure relief valves for use on electronics cases, munitions cases, pressure vessels, transportation container cases, escape slides, and many other medical and non-medical applications.
The Company market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It sells its products through a sales force which consists of direct sales personnel, independent sales representatives and distributors. It offers customer service, training and education, and technical support such as field service, spare parts, maintenance and repair for certain of its products. The Company�� medical products and other components are produced at facilities in ! Florida, ! Alabama and Texas.
Advisors' Opinion:- [By Seth Jayson]
There's no foolproof way to know the future for ATRION (Nasdaq: ATRI ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.
Top 10 Warren Buffett Companies For 2014: Standard Parking Corporation(STAN)
Standard Parking Corporation provides parking management, ground transportation, and other ancillary services to commercial, institutional, and municipal clients in the United States and Canada. Its services include collection and deposit of parking revenues; daily housekeeping; restriping of the parking stalls; maintenance of parking equipment, such as ticket dispensing machines, parking gate arms, and fee computers; painting of walkways, curbs, ceilings, walls, and other facility surfaces; and snow removal from sidewalks and driveways. The company also provides shuttle bus vehicles and drivers to operate them in support of on-airport car rental operations, as well as private off-airport parking locations; and ancillary ground transportation services at airports, such as taxi and livery dispatch, concierge-type ground transportation information, and support services for arriving passengers. In addition, it offers shuttle bus services, on-street parking meter collection, a nd other parking enforcement services for municipalities; and valet parking and shuttle bus services for the medical center and hospital markets. The company serves private and public owners, municipalities, managers and developers of office buildings, residential properties, commercial properties, shopping centers and other retail properties, sports and special event complexes, hotels, and hospitals and medical centers. As of December 31, 2011, it managed approximately 2,200 parking facility locations containing approximately 1.2 million parking spaces in approximately 345 cities; operated 147 parking-related service centers serving 61 airports; and a fleet of approximately 550 shuttle buses. The company was founded in 1929 and is headquartered in Chicago, Illinois.
Advisors' Opinion:- [By Namitha Jagadeesh]
A gauge of banking shares in the FTSE 350 Index reversed earlier gains, declining 0.5 percent. Standard Chartered Plc (STAN) fell 1.8 percent to 1,470 pence and Royal Bank of Scotland Group Plc lost 2.6 percent to 276.7 pence.
Top 10 Warren Buffett Companies For 2014: Vera Bradley Inc.(VRA)
Vera Bradley, Inc., through its subsidiary, Vera Bradley Designs, Inc., engages in the design, production, marketing, and retail of functional accessories for women under the ?Vera Bradley? brand. Its products include a range of handbags, accessories, and travel and leisure items. The company sells its products to independent retailers located in the United States, as well as to national retailers and third party e-commerce sites. As of January 29, 2011, Vera Bradley, Inc. sold its products directly through 35 full-price stores, 4 outlet stores, verabradley.com, and an annual outlet sale in Fort Wayne, Indiana. The company was founded in 1982 and is headquartered in Fort Wayne, Indiana.
Advisors' Opinion:- [By Ben Levisohn]
At first glance, Vera Bradley’s (VRA) earnings report looked great. The retailer reported a profit of 37 cents a share, above analyst forecasts of 32 cents.
But in the what-have-you-done-for-me-lately world of the stock market, that was the past, and the present and future, well they don’t look so hot. For the third quarter, the Vera Bradley, which competes against Coach (COH) and Michael Kors (KORS), among others, now expects sales between�$128 million to $130 million, below forecasts for about $147 million, and a profit of 30 cents to 35 cents, below forecasts for a 48-cent profit. In 2014, Vera Bradley expects sales of�$535 million to $540 million, below forecasts for $575, while its earnings should come in between�$1.47 and $1.52, below expectations of $1.72.�And did I mention that its margins are expected to decline too?�
Put it all together and you have a recipe for a big drop. Vera Bradley’s shares have plunged 10% to $17.50 in after-hours trading.
Ouch.
- [By Marshall Hargrave]
This company is Vera Bradley (NYSE: VRA), which, with a short interest of more than 50%, is one of the most shorted stocks in the market. While VRA has more than disappointed investors over the past 12 months, the market could be offering investors a great entry point for the long term.
- [By Eric Volkman]
Add Vera Bradley (NASDAQ: VRA ) to the list of publicly traded companies on the lookout for a new chief executive. Current CEO Michael Ray has notified the company that he will retire, and Vera Bradley has formed a search committee to hunt for a successor, with the aid of executive search concern Spencer Stuart.
- [By Lee Jackson]
Jefferies also highlighted three other names in its report that also ranked extremely high when run through its metrics screen. Abercrombie & Fitch Co. (NYSE: ANF), Francesca�� Holding Corp. (NASDAQ: FRAN) and Vera Bradley Inc. (NASDAQ: VRA) could all draw the attention of private equity firms looking for a specialty retail play.
Top 10 Warren Buffett Companies For 2014: Central Garden & Pet Company(CENT)
Central Garden & Pet Company produces and sells products for the pet, and lawn and garden supplies industries primarily in the United States. The company?s pet supplies products comprise products for dogs and cats, including edible bones, premium healthy edible and non-edible chews, dog and cat food and treats, leashes, collars, toys, pet carriers, grooming supplies, and other accessories; products for birds, small animals, and specialty pets, such as food, cages and habitats, toys, chews, and related accessories; animal and household health, and insect control products; products for fish, reptiles, and other aquarium-based pets comprising aquariums, furniture and lighting fixtures, pumps, filters, water conditioners, food and supplements, and information and knowledge resources; and products for horses and livestock. It sells its pet supplies products under the Adams, Altosid, Aqueon, Avoderm, BioSpot, Breeder?s Choice, Coralife, Farnam, Four Paws, Interpet, Kaytee, Ken t Marine, Nylabone, Oceanic Systems, Pet Select, Pre-Strike, Pinnacle, Super Pet, TFH, Zilla, and Zodiac brand names. The company?s lawn and garden supplies products include grass seed; wild bird feed, bird feeders, bird houses, and other birding accessories; weed, grass, ant and other herbicide, insecticide, and pesticide products; and decorative outdoor lifestyle and lighting products, such as pottery, trellises and other wood products, and holiday lighting products. It offers its lawn and garden supplies products under the AMDRO, GKI/Bethlehem Lighting, Grant?s, Ironite, Lilly Miller, Matthews Four Seasons, New England Pottery, Norcal Pottery, Pennington, Over?n Out, Sevin, Smart Seed, and The Rebels brand names. It sells its products principally to independent pet and garden distributors, national and regional retail chains, grocery stores, mass merchants, home improvement centers, nurseries, and garden supply retailers. The company was founded in 1955 and is based in Walnut Creek, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Central Garden & Pet (Nasdaq: CENT ) , whose recent revenue and earnings are plotted below. - [By Garrett Cook]
Shares of Central Garden & Pet Company (NASDAQ: CENT) got a boost, shooting up 7.78 percent to $9.70 after Harbinger Group offered to buy Central Garden & Pet Co for $10 per share.
No comments:
Post a Comment